Verona Pharma plc Verona Pharma To Announce Interim Results For Nine Months Ended September 30, 2018 And Provide Clinical Dev...

 
TIDMVRP 
 
   LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that it will report its audited 
financial results for the nine months ended September 30, 2018 on 
Tuesday, November 6, 2018. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesday, 
November 6, 2018 to discuss the nine months financial results and 
provide a clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 8100157 and dialing the following numbers: 
 
 
   -- 800-289-0571 or 929-477-0324 for callers in the United States 
 
   -- 0800 358 6377 or 44 (0)330 336 9126 for callers in the United Kingdom 
 
   -- 0800 589 4609 or 49 (0)69 2222 25577 for calls in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at www.veronapharma.com and clicking on the "Events and 
presentations" link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
www.veronapharma.com. 
 
   About Verona Pharma plc and RPL554 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual 
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a 
bronchodilator and an anti-inflammatory agent in a single compound. In 
previous clinical trials, RPL554 has been observed to result in 
bronchodilator effects when used alone or as an add-on treatment to 
other COPD bronchodilators. It has shown clinically meaningful and 
statistically significant improvements in lung function when 
administered in addition to frequently used short- and long-acting 
bronchodilators, such as tiotropium (Spiriva(R)), compared with such 
bronchodilators administered as a single agent. RPL554 improved FEV(1) 
over four weeks in patients with moderate-to-severe COPD when compared 
to placebo and improved COPD symptoms and Quality of Life in a Phase 2b 
multicenter European study performed in 403 patients. In addition, 
RPL554 has shown anti-inflammatory effects in a standard challenge study 
with COPD-like inflammation in human subjects. RPL554 has been well 
tolerated in these studies and has a favorable safety and tolerability 
profile, having been administered to more than 730 subjects in 12 
clinical trials. Verona Pharma is developing RPL554 for the treatment of 
COPD, cystic fibrosis ("CF"), and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
                                                    4200 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 
 and UK Broker)                                     7710 7600 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
FTI Consulting (UK Media and Investor enquiries)   Tel: [phone] 
                                                    1000 
Simon Conway / Natalie Garland-Collins             [e-mail] 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                        Tel: [phone] 
                                                    [e-mail] 
Stephanie Carrington                               Tel. [phone] 
                                                    [e-mail] 
 
 
 
 

(END) Dow Jones Newswires

October 30, 2018 02:00 ET (06:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.